The tens of billions of dollars in the drug market adds another competitor

Recently, the website of the Food and Drug Administration showed that Chia Tai Tianqing's adalimumab biosimilar has been approved for marketing
.
It is understood that this is the sixth adalimumab approved for marketing in China, and it is also the first biosimilar drug approved for marketing by Chia Tai Tianqing Pharmaceutical
.
According to the data, the research and development company of adalimumab is AbbVie.
The drug is a fully human anti-tumor necrosis factor alpha (TNF-α) monoclonal antibody, and the trade name is Humira
.
Since Humira was approved for marketing in 2002, it has been approved for more than 17 different indications, and has been approved in China for rheumatoid arthritis, ankylosing spondylitis, moderate to severe plaque psoriasis, 8 indications including Roan's disease
.
It is understood that Humira was the first to be approved for listing in the United States in December 2002, and subsequently listed in the European Union, Japan and other countries
.
Since its launch, Humira’s sales have remained high.
Even with the competition from biosimilars in Europe, sales in 2020 will still be as high as $19.
8 billion, of which the U.
S.
market accounts for $16.
1 billion
.
In February 2010, Humira was approved for import in China, and in 2019, the price was reduced by 59% through negotiation and included in the national medical insurance
.
With the help of medical insurance and biosimilars, adalimumab will rapidly increase in volume in the domestic market in 2020
.
Data show that in 2020, the sales of terminal adalimumab in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 1 billion yuan, a year-on-year increase of 995.
88%
.
In 2020, the sales of terminal adalimumab in urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will also be close to 1 billion yuan, a year-on-year increase of 995.
88%
.
The huge market will naturally attract more and more companies to enter the market.
Currently, in China, in addition to AbbVie's original research imports and the approved Chia Tai Tianqing, four adalimumab-like drugs have been approved in China.
Approved listings from Bio-Tech, Hisun Bio, Innovent Bio, and Henlius
.
In addition, there are more than 10 domestic companies that are developing adalimumab biosimilars.
Among them, Junshi Bio and Shenzhou Cell's product marketing applications have been accepted
.
On the whole, it is generally believed in the industry that as more and more adalimumab biosimilars are approved for the market, they will further enrich clinical treatment options and improve drug availability for patients at more competitive market prices.
It triggered a reshuffle in the domestic market and caused direct competitive pressure on AbbVie's original research drug Humira
.
In addition, it is worth noting that as biosimilars are an important category in the field of biological medicine, as more and more products are launched, the basic conditions for entering the centralized procurement have become increasingly mature
.
Therefore, under the background that the industry's voice for the inclusion of biological drugs in centralized procurement has been increasing, the industry expects that three or more companies have met the conditions for centralized procurement of adalimumab.
Once the centralized procurement of biosimilar drugs In the case of kicking off, there is a very high possibility that it will be included, which will be a big challenge for all related companies
.